Suppr超能文献

类风湿关节炎的温泉疗法(或水疗)

Balneotherapy (or spa therapy) for rheumatoid arthritis.

作者信息

Verhagen Arianne P, Bierma-Zeinstra Sita M A, Boers Maarten, Cardoso Jefferson R, Lambeck Johan, de Bie Rob, de Vet Henrica C W

机构信息

Department of General Practice, Erasmus Medical Center, PO Box 2040, Rotterdam, Netherlands, 3000 CA.

出版信息

Cochrane Database Syst Rev. 2015 Apr 11;2015(4):CD000518. doi: 10.1002/14651858.CD000518.pub2.

Abstract

BACKGROUND

No cure for rheumatoid arthritis (RA) is known at present, so treatment often focuses on management of symptoms such as pain, stiffness and mobility. Treatment options include pharmacological interventions, physical therapy treatments and balneotherapy. Balneotherapy is defined as bathing in natural mineral or thermal waters (e.g. mineral baths, sulphur baths, Dead Sea baths), using mudpacks or doing both. Despite its popularity, reported scientific evidence for the effectiveness or efficacy of balneotherapy is sparse. This review, which evaluates the effects of balneotherapy in patients with RA, is an update of a Cochrane review first published in 2003 and updated in 2008.

OBJECTIVES

To perform a systematic review on the benefits and harms of balneotherapy in patients with RA in terms of pain, improvement, disability, tender joints, swollen joints and adverse events.

SEARCH METHODS

We searched the Cochrane 'Rehabilitation and Related Therapies' Field Register (to December 2014), the Cochrane Central Register of Controlled Trials (2014, Issue 1), MEDLIINE (1950 to December 2014), EMBASE (1988 to December 2014), the Cumulative Index to Nursing and Allied Health Literature (CINAHL) (1982 to December 2014), the Allied and Complementary Medicine Database (AMED) (1985 to December 2014), PsycINFO (1806 to December 2014) and the Physiotherapy Evidence Database (PEDro). We applied no language restrictions; however, studies not reported in English, Dutch, Danish, Swedish, Norwegian, German or French are awaiting assessment. We also searched the World Health Organization (WHO) International Clinical Trials Registry Platform for ongoing and recently completed trials.

SELECTION CRITERIA

Studies were eligible if they were randomised controlled trials (RCTs) consisting of participants with definitive or classical RA as defined by the American Rheumatism Association (ARA) criteria of 1958, the ARA/American College of Rheumatology (ACR) criteria of 1988 or the ACR/European League Against Rheumatism (EULAR) criteria of 2010, or by studies using the criteria of Steinbrocker.Balneotherapy had to be the intervention under study, and had to be compared with another intervention or with no intervention.The World Health Organization (WHO) and the International League Against Rheumatism (ILAR) determined in 1992 a core set of eight endpoints in clinical trials concerning patients with RA. We considered pain, improvement, disability, tender joints, swollen joints and adverse events among the main outcome measures. We excluded studies when only laboratory variables were reported as outcome measures.

DATA COLLECTION AND ANALYSIS

Two review authors independently selected trials, performed data extraction and assessed risk of bias. We resolved disagreements by consensus and, if necessary, by third party adjudication.

MAIN RESULTS

This review includes two new studies and a total of nine studies involving 579 participants. Unfortunately, most studies showed an unclear risk of bias in most domains. Four out of nine studies did not contribute to the analysis, as they presented no data.One study involving 45 participants with hand RA compared mudpacks versus placebo. We found no statistically significant differences in terms of pain on a 0 to 100-mm visual analogue scale (VAS) (mean difference (MD) 0.50, 95% confidence interval (CI) -0.84 to 1.84), improvement (risk ratio (RR) 0.96, 95% CI 0.54 to 1.70) or number of swollen joints on a scale from 0 to 28 (MD 0.60, 95% CI -0.90 to 2.10) (very low level of evidence). We found a very low level of evidence of reduction in the number of tender joints on a scale from 0 to 28 (MD -4.60, 95% CI -8.72 to -0.48; 16% absolute difference). We reported no physical disability and presented no data on withdrawals due to adverse events or on serious adverse events.Two studies involving 194 participants with RA evaluated the effectiveness of additional radon in carbon dioxide baths. We found no statistically significant differences between groups for all outcomes at three-month follow-up (low to moderate level of evidence). We noted some benefit of additional radon at six months in terms of pain frequency (RR 0.6, 95% CI 0.4 to 0.9; 31% reduction; improvement in one or more points (categories) on a 4-point scale; moderate level of evidence) and 9.6% reduction in pain intensity on a 0 to 100-mm VAS (MD 9.6 mm, 95% CI 1.6 to 17.6; moderate level of evidence). We also observed some benefit in one study including 60 participants in terms of improvement in one or more categories based on a 4-point scale (RR 2.3, 95% CI 1.1 to 4.7; 30% absolute difference; low level of evidence). Study authors did not report physical disability, tender joints, swollen joints, withdrawals due to adverse events or serious adverse events.One study involving 148 participants with RA compared balneotherapy (seated immersion) versus hydrotherapy (exercises in water), land exercises or relaxation therapy. We found no statistically significant differences in pain on the McGill Questionnaire or in physical disability (very low level of evidence) between balneotherapy and the other interventions. No data on improvement, tender joints, swollen joints, withdrawals due to adverse events or serious adverse events were presented.One study involving 57 participants with RA evaluated the effectiveness of mineral baths (balneotherapy) versus Cyclosporin A. We found no statistically significant differences in pain intensity on a 0 to 100-mm VAS (MD 9.64, 95% CI -1.66 to 20.94; low level of evidence) at 8 weeks (absolute difference 10%). We found some benefit of balneotherapy in overall improvement on a 5-point scale at eight weeks of 54% (RR 2.35, 95% CI 1.44 to 3.83). We found no statistically significant differences (low level of evidence) in the number of swollen joints, but some benefit of Cyclosporin A in the number of tender joints (MD 8.9, 95% CI 3.8 to 14; very low level of evidence). Physical disability, withdrawals due to adverse events and serious adverse events were not reported.

AUTHORS' CONCLUSIONS: Overall evidence is insufficient to show that balneotherapy is more effective than no treatment, that one type of bath is more effective than another or that one type of bath is more effective than mudpacks, exercise or relaxation therapy.

摘要

背景

目前尚无治愈类风湿性关节炎(RA)的方法,因此治疗通常侧重于疼痛、僵硬和活动能力等症状的管理。治疗选择包括药物干预、物理治疗和浴疗法。浴疗法定义为在天然矿泉或温泉中沐浴(如矿泉浴、硫磺浴、死海浴)、使用泥敷剂或两者兼用。尽管浴疗法很受欢迎,但关于其有效性或疗效的科学证据却很少。本综述评估了浴疗法对RA患者的影响,是对2003年首次发表并于2008年更新的Cochrane综述的更新。

目的

对浴疗法在RA患者中的益处和危害进行系统评价,评价指标包括疼痛、改善情况、残疾程度、压痛关节数、肿胀关节数和不良事件。

检索方法

我们检索了Cochrane“康复及相关疗法”领域注册库(截至2014年12月)、Cochrane对照试验中心注册库(2014年第1期)、MEDLINE(1950年至2014年12月)、EMBASE(1988年至2014年12月)、护理学与健康相关文献累积索引(CINAHL)(1982年至2014年12月)、补充与替代医学数据库(AMED)(1985年至2014年12月)、PsycINFO(1806年至2014年12月)和物理治疗证据数据库(PEDro)。我们没有设置语言限制;然而未以英语、荷兰语、丹麦语、瑞典语、挪威语、德语或法语报道的研究尚待评估。我们还检索了世界卫生组织(WHO)国际临床试验注册平台,以查找正在进行和最近完成的试验。

入选标准

如果研究为随机对照试验(RCT),且参与者符合1958年美国风湿病协会(ARA)标准、1988年ARA/美国风湿病学会(ACR)标准或2010年ACR/欧洲抗风湿病联盟(EULAR)标准定义的明确或经典RA,或者符合Steinbrocker标准,则这些研究符合入选条件。浴疗法必须是所研究的干预措施,并且必须与另一种干预措施或不进行干预进行比较。世界卫生组织(WHO)和国际抗风湿病联盟(ILAR)在1992年确定了关于RA患者临床试验的一组八项核心终点指标。我们将疼痛、改善情况、残疾程度、压痛关节数、肿胀关节数和不良事件作为主要结局指标。当仅报告实验室变量作为结局指标时,我们排除这些研究。

数据收集与分析

两位综述作者独立选择试验、进行数据提取并评估偏倚风险。我们通过共识解决分歧,必要时由第三方裁决。

主要结果

本综述纳入了两项新研究,共九项研究,涉及579名参与者。遗憾的是,大多数研究在大多数领域的偏倚风险不明确。九项研究中有四项未纳入分析,因为它们未提供数据。一项涉及45名手部RA患者的研究比较了泥敷剂与安慰剂。我们发现在0至100毫米视觉模拟量表(VAS)上的疼痛程度(平均差(MD)0.50,95%置信区间(CI)-0.84至1.84)、改善情况(风险比(RR)0.96,95%CI 0.54至1.70)或0至28分肿胀关节数(MD 0.60,95%CI -0.90至2.10)方面无统计学显著差异(证据质量极低)。我们发现0至28分压痛关节数减少的证据质量极低(MD -4.60,95%CI -8.72至-0.48;绝对差异16%)。我们未报告身体残疾情况,也未提供因不良事件导致的退出或严重不良事件的数据。两项涉及194名RA患者的研究评估了二氧化碳浴中添加氡的有效性。我们发现在三个月随访时,两组在所有结局指标上均无统计学显著差异(证据质量低至中等)。我们注意到在六个月时,添加氡在疼痛频率方面有一些益处(RR 0.6,95%CI 0.4至0.9;降低31%;在4分制量表上改善一个或多个分数(类别);证据质量中等),在0至100毫米VAS上疼痛强度降低9.6%(MD 9.6毫米,95%CI 1.6至17.6;证据质量中等)。我们还在一项包括60名参与者的研究中观察到在基于4分制量表的一个或多个类别改善方面有一些益处(RR 2.3,95%CI 1.1至4.7;绝对差异30%;证据质量低)。研究作者未报告身体残疾、压痛关节数、肿胀关节数、因不良事件导致的退出或严重不良事件。一项涉及148名RA患者的研究比较了浴疗法(坐式浸泡)与水疗法(水中运动)、陆地运动或放松疗法。我们发现在麦吉尔问卷上的疼痛程度或身体残疾方面,浴疗法与其他干预措施之间无统计学显著差异(证据质量极低)。未提供关于改善情况、压痛关节数、肿胀关节数、因不良事件导致的退出或严重不良事件的数据。一项涉及57名RA患者的研究评估了矿泉浴(浴疗法)与环孢素A的有效性。我们发现在8周时,0至100毫米VAS上的疼痛强度无统计学显著差异(MD 9.64,95%CI -1.66至20.94;证据质量低)(绝对差异10%)。我们发现在八周时,浴疗法在5分制总体改善方面有一些益处,改善率为54%(RR 2.35,95%CI 1.44至3.83)。我们发现在肿胀关节数方面无统计学显著差异(证据质量低),但环孢素A在压痛关节数方面有一些益处(MD 8.9,95%CI 3.8至14;证据质量极低)。未报告身体残疾、因不良事件导致的退出和严重不良事件。

作者结论

总体证据不足,无法表明浴疗法比不治疗更有效,一种浴疗法比另一种更有效,或者一种浴疗法比泥敷剂、运动或放松疗法更有效。

相似文献

1
Balneotherapy (or spa therapy) for rheumatoid arthritis.
Cochrane Database Syst Rev. 2015 Apr 11;2015(4):CD000518. doi: 10.1002/14651858.CD000518.pub2.
3
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Cochrane Database Syst Rev. 2020 Jan 9;1(1):CD011535. doi: 10.1002/14651858.CD011535.pub3.
4
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2.
5
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
6
Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.
Cochrane Database Syst Rev. 2020 Oct 19;10(10):CD012859. doi: 10.1002/14651858.CD012859.pub2.
7
Exercise for hand osteoarthritis.
Cochrane Database Syst Rev. 2017 Jan 31;1(1):CD010388. doi: 10.1002/14651858.CD010388.pub2.
8
Celecoxib for osteoarthritis.
Cochrane Database Syst Rev. 2017 May 22;5(5):CD009865. doi: 10.1002/14651858.CD009865.pub2.
10
Hyaluronic acid and other conservative treatment options for osteoarthritis of the ankle.
Cochrane Database Syst Rev. 2015 Oct 17;2015(10):CD010643. doi: 10.1002/14651858.CD010643.pub2.

引用本文的文献

1
Recent development of mitochondrial metabolism and dysfunction in osteoarthritis.
Front Pharmacol. 2025 Feb 13;16:1538662. doi: 10.3389/fphar.2025.1538662. eCollection 2025.
2
Efficacy and safety of balneotherapy in rheumatology: a systematic review and meta-analysis.
BMJ Open. 2025 Feb 26;15(2):e089597. doi: 10.1136/bmjopen-2024-089597.
5
The role and intervention of mitochondrial metabolism in osteoarthritis.
Mol Cell Biochem. 2024 Jun;479(6):1513-1524. doi: 10.1007/s11010-023-04818-9. Epub 2023 Jul 24.
6
Overview of Cochrane Systematic Reviews of rehabilitation interventions for persons with rheumatoid arthritis: a mapping synthesis.
Eur J Phys Rehabil Med. 2023 Apr;59(2):259-269. doi: 10.23736/S1973-9087.22.07833-9. Epub 2023 Feb 2.
7
Balneotherapy for chronic venous insufficiency.
Cochrane Database Syst Rev. 2023 Jan 9;1(1):CD013085. doi: 10.1002/14651858.CD013085.pub3.
9
Comparative efficacy and acceptability of non-pharmacological interventions in fibromyalgia: Protocol for a network meta-analysis.
PLoS One. 2022 Oct 3;17(10):e0274406. doi: 10.1371/journal.pone.0274406. eCollection 2022.
10
Comparison of Blood Pressure and Pulse Adaptations Between Younger and Older Patients During Balneotherapy With Physiotherapy.
J Chiropr Med. 2022 Sep;21(3):197-203. doi: 10.1016/j.jcm.2022.02.012. Epub 2022 Jun 6.

本文引用的文献

1
Long-term benefits of radon spa therapy in rheumatic diseases: results of the randomised, multi-centre IMuRa trial.
Rheumatol Int. 2013 Nov;33(11):2839-50. doi: 10.1007/s00296-013-2819-8. Epub 2013 Jul 18.
2
Muscle relaxants for pain management in rheumatoid arthritis.
Cochrane Database Syst Rev. 2012 Jan 18;1(1):CD008922. doi: 10.1002/14651858.CD008922.pub2.
3
Neuromodulators for pain management in rheumatoid arthritis.
Cochrane Database Syst Rev. 2012 Jan 18;1(1):CD008921. doi: 10.1002/14651858.CD008921.pub2.
4
The pathogenesis of rheumatoid arthritis.
N Engl J Med. 2011 Dec 8;365(23):2205-19. doi: 10.1056/NEJMra1004965.
6
Opioid therapy for treating rheumatoid arthritis pain.
Cochrane Database Syst Rev. 2011 Nov 9(11):CD003113. doi: 10.1002/14651858.CD003113.pub3.
8
Pain management for rheumatoid arthritis and cardiovascular or renal comorbidity.
Cochrane Database Syst Rev. 2011 Oct 5(10):CD008952. doi: 10.1002/14651858.CD008952.pub2.
9
Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
Cochrane Database Syst Rev. 2011 Feb 16(2):CD007649. doi: 10.1002/14651858.CD007649.pub2.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验